CytoSorbents“ flagship product lowers the risks caused by life threatening inflammation
Munich, February 20, 2019 – CytoSorbents, a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has selected Lucy Turpin Communications (LTC) as its agency of record for Europe.
LTC will be responsible for a comprehensive range of marketing services, including marketing communications, Social Media activities, etc. The agency will be working in close collaboration, both strategically and within various campaigns with Dr. Christian Steiner, Senior SVP Sales & Marketing of CytoSorbents Corporation and Managing Director of CytoSorbents Europe GmbH. The agency will be establishing and professionalizing the company“s marketing activities. Apart from making the CytoSorb therapy visible in the healthcare ecosystem, LTC will be positioning CytoSorbents as a relevant player with a solution for the European medical community.
CytoSorbents“ flagship product, CytoSorb©, is a blood purifying therapy – based on an extracorporeal cytokine adsorber – designed for cardiac surgeons, cardiologists and intensive care specialists. These doctors aim to reduce the risks of deadly inflammation, known as „cytokine-release syndrome“ in critically-ill patients. CytoSorb is designed to lower the probability and harmful impact of an immune over-reaction in severe acute diseases such as septic shock, which can lead to life-threatening multiple organ failure if left untreated.
The purification technology is based on a cartridge containing biocompatible and highly porous polymer beads that act like sponges and actively remove harmful substances from the blood. Each of these spherical beads is approximately the size of a grain of salt and synthesized to contain millions of optimally-sized pores and channels. These pores and channels collectively have a massive surface area that enable the bead to behave like a tiny sponge to safely bind and effectively remove a broad range of inflammatory and toxic substances from whole blood.
Dr. Christian Steiner, SVP Sales & Marketing and Managing Director CytoSorbents Europe, said, „We decided on LTC because of its successful medical industry practice, compelling reputation and obvious professional approach. There was an immediate understanding of our vision that the broad introduction of CytoSorb therapy will potentially create a disruptive change of critical care medicine.“
„It is very exciting for us to be able to contribute to bringing CytoSorbents“ truly innovative solution to the European healthcare market,“ said Thomas Hahnel, General Manager of LTC. „Our goal is to create a critical mass of awareness for the therapy and its benefits.“
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in new technologies and therapies in intelligent blood purification. CytoSorbents Europe GmbH is a hundred percent daughter company of CytoSorbents Corporation and coordinates the introduction and commercialization of CytoSorbents products worldwide.
Its flagship product, CytoSorb® is the first specifically-approved extracorporeal cytokine absorber in the European Union and it is distributed in more than 50 countries worldwide. CytoSorb was designed to reduce the „cytokine storm“ or „cytokine release syndrome,“ which is a major element of the deadly inflammation often seen in critically-ill patients in the intensive care unit (ICU) and those undergoing complex open heart surgery. CytoSorbents“ purification technologies are based on biocompatible, highly porous polymer beads that act like sponges and actively remove harmful substances from the blood. CytoSorb has been used in more than 56,000 human treatments to date.
CytoSorbents technologies have received non-dilutive grant, contract, and other funding of approximately $25 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others.
About Lucy Turpin Communications:
Founded in 1995, Lucy Turpin Communications is a leading PR, Social Media and Marketing Communications agency specialized in the DACH market ecosystem. Its B2B and B2C clients – most often positioned in High Tech sectors such as ITC, Electronics, Life Sciences, Clean Tech and Industrial Solutions – reap valuable benefits from LTC“s strategic approach, creativity, experience and passion for communications. www.lucyturpin.com/en; Twitter: @LTCComms
Die Bildrechte liegen bei dem Verfasser der Mitteilung.